Stock-Based Compensation for AstraZeneca (AZN)
Stock-Based Compensation for AstraZeneca (AZN): headline value $0. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
AZN
Currently viewingStock-Based CompensationSwitch metric
Latest period
$0
YoY change
N/A
5Y CAGR
-100.0%
Peak year (2022)
$619.00M
Latest annual
$0
Stock-Based Compensation history chart for AstraZeneca (AZN) from 1990 to 2025
Stock-Based Compensation history table for AstraZeneca (AZN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $0 | — | ||
| 2024 | $0 | -100.0% | ||
| 2023 | $579.00M | -6.5% | ||
| 2022 | $619.00M | +0.7% | ||
| 2021 | $615.00M | +122.0% | ||
| 2020 | $277.00M | +6.9% | ||
| 2019 | $259.00M | — | ||
| 2018 | $0 | — | ||
| 2017 | $0 | — | ||
| 2016 | $0 | — | ||
| 2015 | $0 | — | ||
| 2014 | $0 | — | ||
| 2013 | $0 | — | ||
| 2012 | $0 | — | ||
| 2011 | $0 | — | ||
| 2010 | $0 | — | ||
| 2009 | $0 | — | ||
| 2008 | $0 | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — | ||
| 1990 | $0 | — |
Stock-Based Compensation values are taken from AstraZeneca's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, AstraZeneca (AZN) stock-based compensation totalled $0.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca stock-based compensation compounded at -100.0% per year, with a net decline across the window.
Across the available history, stock-based compensation reached its high of $619.00M in 2022 and its low of $0 in 1990.
AstraZeneca (AZN) sits 5th of 8 Healthcare peers we track on this metric, against a peer median of $313.00M.
AstraZeneca Stock-Based Compensation by Year
AstraZeneca Stock-Based Compensation 2025: $0
AstraZeneca stock-based compensation in 2025 was $0.
AstraZeneca Stock-Based Compensation 2024: $0
AstraZeneca stock-based compensation in 2024 was $0, plunged 100.0% below 2023.
AstraZeneca Stock-Based Compensation 2023: $579.00M
AstraZeneca stock-based compensation in 2023 was $579.00M, declined 6.5% below 2022.
AstraZeneca Stock-Based Compensation 2022: $619.00M
AstraZeneca stock-based compensation in 2022 was $619.00M, edged up 0.7% from 2021. This figure represents the highest annual value in the available history.
AstraZeneca Stock-Based Compensation 2021: $615.00M
AstraZeneca stock-based compensation in 2021 was $615.00M.
See more financial history for AstraZeneca (AZN).
Sector peers — Stock-Based Compensation
Companies in the same sector as AstraZeneca, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $0 | Healthcare |
Frequently asked questions
What is AstraZeneca's stock-based compensation?
Latest reported stock-based compensation for AstraZeneca (AZN) is $0 (period ending December 31, 2025).
What is the long-term growth rate of AstraZeneca stock-based compensation?
AstraZeneca (AZN) stock-based compensation compound annual growth rate is -100.0% over the most recent 5 years available.
When did AstraZeneca stock-based compensation hit its highest annual value?
AstraZeneca stock-based compensation reached its highest annual value of $619.00M in 2022.
What was AstraZeneca stock-based compensation in 2024?
AstraZeneca (AZN) stock-based compensation in 2024 was $0.
What was AstraZeneca stock-based compensation in 2025?
AstraZeneca (AZN) stock-based compensation in 2025 was $0.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
AZN Overview
Company profile, financial tools, and key metrics
AZN Revenue Counter
Earns $1,863 every second. See per minute, hour, and day.
AZN Earnings Counter
Earns $324.23 per second net profit. See per minute, hour, and day.
AZN Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
AZN What If Invested
What if you had invested $1,000? See historical returns from any date.
AZN How It Makes Money
Discover visual breakdown of $58.74B in revenue — where it comes from and where it goes.
AZN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
AZN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
AZN Daily Price Character
Steady · 49.4% historical win rate (green days). Streaks & record days.
AZN Buybacks
0.16% TTM buyback yield. Shareholder yield & SBC comparison.
AZN Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.
AZN Dividend Profile
Yield: 1.73%. Safety: 6/8. See full history.
AZN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
AZN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.